| The adenosine pathway in immuno-oncology B Allard, D Allard, L Buisseret, J Stagg Nature Reviews Clinical Oncology 17 (10), 611-629, 2020 | 431 | 2020 |
| Targeting the CD73-adenosine axis in immuno-oncology D Allard, P Chrobak, B Allard, N Messaoudi, J Stagg Immunology letters 205, 31-39, 2019 | 155 | 2019 |
| CD73–adenosine: a next-generation target in immuno-oncology D Allard, B Allard, PO Gaudreau, P Chrobak, J Stagg Immunotherapy 8 (2), 145-163, 2016 | 153 | 2016 |
| Targeting A2 adenosine receptors in cancer D Allard, M Turcotte, J Stagg Immunology and cell biology 95 (4), 333-339, 2017 | 132 | 2017 |
| CD73 promotes resistance to HER2/ErbB2 antibody therapy M Turcotte, D Allard, D Mittal, Y Bareche, L Buisseret, V José, S Pommey, ... Cancer research 77 (20), 5652-5663, 2017 | 111 | 2017 |
| On the mechanism of anti-CD39 immune checkpoint therapy D Allard, B Allard, J Stagg Journal for immunotherapy of cancer 8 (1), 2020 | 110 | 2020 |
| Targeting the adenosine pathway for cancer immunotherapy A Hammami, D Allard, B Allard, J Stagg Seminars in Immunology 42, 101304, 2019 | 80 | 2019 |
| DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells HL Yau, E Bell, I Ettayebi, FC de Almeida, GM Boukhaled, SY Shen, ... Molecular cell 81 (7), 1469-1483. e8, 2021 | 74 | 2021 |
| PolyI: C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors R Charlebois, B Allard, D Allard, L Buisseret, M Turcotte, S Pommey, ... Cancer research 77 (2), 312-319, 2017 | 45 | 2017 |
| CD73 inhibits cGAS–STING and cooperates with CD39 to promote pancreatic cancer C Jacoberger-Foissac, I Cousineau, Y Bareche, D Allard, P Chrobak, ... Cancer immunology research 11 (1), 56-71, 2023 | 44 | 2023 |
| Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis B Allard, I Cousineau, D Allard, L Buisseret, S Pommey, P Chrobak, ... Oncoimmunology, 2019 | 34 | 2019 |
| High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer Y Bareche, S Pommey, M Carneiro, L Buisseret, I Cousineau, P Thebault, ... Journal for ImmunoTherapy of Cancer 9 (3), 2021 | 21 | 2021 |
| Methods to evaluate the antitumor activity of immune checkpoint inhibitors in preclinical studies B Allard, D Allard, J Stagg The Tumor Microenvironment: Methods and Protocols, 159-177, 2016 | 16 | 2016 |
| Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma B Allard, C Jacoberger-Foissac, I Cousineau, Y Bareche, L Buisseret, ... Cell Reports Medicine 4 (9), 2023 | 12 | 2023 |
| The CD73 immune checkpoint promotes tumor cell metabolic fitness D Allard, I Cousineau, EH Ma, B Allard, Y Bareche, H Fleury, J Stagg eLife 12, e84508, 2023 | 6 | 2023 |
| CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination D Allard, R Charlebois, L Gilbert, J Stagg, P Chrobak Plos one 13 (1), e0191973, 2018 | 4 | 2018 |
| CD73 promotes chronic lymphocytic leukemia D Allard, P Chrobak, Y Bareche, B Allard, P Tessier, MA Bergeron, ... Cancers 14 (13), 3130, 2022 | 3 | 2022 |
| Assessing the efficacy of immune checkpoint inhibitors in preclinical tumor models C Jacoberger-Foissac, B Allard, D Allard, J Stagg The Tumor Microenvironment: Methods and Protocols, 151-169, 2023 | 2 | 2023 |
| Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T Cell Pyrimidine Synthesis D Allard, J Cormery, S Bricha, C Fuselier, F Abbas Aghababazadeh, ... Cancer Research, 2024 | | 2024 |